On May, 8 Akebia Therapeutics, Inc. (AKBA) Analysts See $-0.01 EPS

April 16, 2018 - By Andrea Pope

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Corporate Logo
Big Money Sentiment decreased to 1.63 in 2017 Q4. It has change of 0.60, from 2017Q3’s 2.23. The ratio turned negative due to Akebia Therapeutics, Inc. positioning: 15 sold and 28 reduced. 26 funds acquired positions and 44 increased positions. Investors holded 28.78 million in 2017Q3 but now own 30.27 million shares or 5.16% more.
Eagle Asset Management holds 2.72M shs or 0.22% of its capital. The Massachusetts-based Panagora Asset Management has invested 0.01% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Numeric Limited Liability Corporation has invested 0.02% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Hancock Holdings stated it has 0.04% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Amer Century Cos Inc accumulated 0.01% or 353,111 shs. Secor Cap Advisors Limited Partnership reported 0.03% of its capital in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Alliancebernstein L P reported 43,200 shs stake. American Intl Group Incorporated Inc has 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Brown Brothers Harriman owns 113 shs or 0% of their US capital. Geode Cap Mgmt Lc reported 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Great West Life Assurance Can has 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 4,675 shs. Balyasny Asset Mgmt Ltd reported 12,049 shs. Marshall Wace Limited Liability Partnership reported 204,196 shs or 0.13% of all its holdings. Northern holds 0% of its capital in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 513,456 shs. Natl Bank Of Ny Mellon Corporation accumulated 0% or 251,393 shs.

Akebia Therapeutics, Inc. had 1 insider sale and 0 buys since February 15, 2018. This’s net activity of $14,620.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is expected to publish earnings on May, 8., RTT reports. Analysts forecast $-0.01 earnings per share. That’s $1.14 up or 99.13 % from 2017’s earnings of $-1.15. Last quarter $0.25 earnings per share was reported. Analysts forecasts -104.00 % negative EPS growth this quarter. AKBA reached $9.95 on during the last trading session after $0.18 change.Akebia Therapeutics, Inc. has volume of 402,481 shares. Since April 16, 2017 AKBA has risen 5.85% and is uptrending. The stock underperformed the S&P500 by 5.70%.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

In total 4 analysts cover Akebia Therapeutics (NASDAQ:AKBA). “Buy” rating has 3, “Sell” are 0, while 1 are “Hold”. 75% are bullish. 4 are the (NASDAQ:AKBA)’s analyst reports since November 2, 2017 according to StockzIntelligence Inc. On Thursday, December 7 the company was initiated by BTIG Research. On Thursday, November 2 RBC Capital Markets maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) with “Hold” rating. On Monday, December 18 Piper Jaffray initiated the shares of AKBA in report with “Buy” rating. In Wednesday, March 7 report Mizuho maintained the stock with “Buy” rating.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology.The firm is valued at $558.32 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients.Currently it has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.